{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T04:24:34Z","timestamp":1683174274439},"reference-count":39,"publisher":"SLACK, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychosoc Nurs Ment Health Serv"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>\n            Opioid use disorder (OUD) and overdose deaths are increasingly prevalent among youth and young adults; however, the evidence-based medication-assisted treatments (MATs) that have U.S. Food and Drug Administration approval for the treatment of adults are not approved for persons aged 16 to 18 years. New guidelines from the American Society of Addiction Medicine provide information on the risks and benefits of MAT with youth and young adults that help guide decision making. Clinical decisions require a thorough physical and psychiatric evaluation, risk\/benefit analysis in treatment planning, and collaboration with youth and young adults to engage support systems. The current article presents an overview of the three available maintenance treatments for youth and young adults with OUD. [\n            <jats:italic>Journal of Psychosocial Nursing and Mental Health Services, 59<\/jats:italic>\n            (5), 9\u201313.]\n          <\/jats:p>","DOI":"10.3928\/02793695-20210415-04","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T13:55:47Z","timestamp":1620222947000},"page":"9-13","source":"Crossref","is-referenced-by-count":0,"title":["Medication Treatments for Youth and Young Adults With Opioid Use Disorder"],"prefix":"10.3928","volume":"59","author":[{"given":"Ilya","family":"Rozenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Kverno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","author":"American Association of Child and Adolescent Psychiatry","year":"2016","unstructured":"American Association of Child and Adolescent Psychiatry. (2016). Teen brain, behavior, problem solving, and decision-making. https:\/\/www.aacap.org\/aacap\/families_and_youth\/facts_for_families\/fff-guide\/the-teen-brain-behavior-problem-solving-and-decision-making-095.aspx","journal-title":"Teen brain, behavior, problem solving, and decision-making"},{"key":"e_1_3_1_3_1","author":"American Society of Addiction Medicine","year":"2020","unstructured":"American Society of Addiction Medicine. (2020). National practice guideline for the treatment of opioid use disorder\u20142020 focused update. https:\/\/www.asam.org\/docs\/default-source\/quality-science\/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2","journal-title":"National practice guideline for the treatment of opioid use disorder\u20142020 focused update"},{"key":"e_1_3_1_4_1","volume-title":"The spike in drug overdose deaths during the COVID-19 pandemic and policy options to move forward.","author":"Baumgartner J. C.","year":"2021","unstructured":"Baumgartner, J. C., & Radley, D. C. (2021). The spike in drug overdose deaths during the COVID-19 pandemic and policy options to move forward. Improving Health Care Quality Blog, The Commonwealth Fund. https:\/\/www.commonwealthfund.org\/blog\/2021\/spike-drug-overdose-deaths-during-covid-19-pandemic-and-policy-options-move-forward#:\u223c:text=Our%20estimates%20show%20that%20total,had%20never%20risen%20above%206%2C300"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000388"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2019.80.393"},{"key":"e_1_3_1_7_1","unstructured":"Centers for Disease Control and Prevention. (2020a). Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. https:\/\/emergency.cdc.gov\/han\/2020\/han00438.asp"},{"key":"e_1_3_1_8_1","author":"Centers for Disease Control and Prevention","year":"2020","unstructured":"Centers for Disease Control and Prevention. (2020b). Opioid overdose: Drug overdose deaths. https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html","journal-title":"Opioid overdose: Drug overdose deaths"},{"key":"e_1_3_1_9_1","author":"Centers for Disease Control and Prevention","year":"2020","unstructured":"Centers for Disease Control and Prevention. (2020c). Overdose deaths accelerating during COVID-19: Expanded prevention efforts needed. https:\/\/www.cdc.gov\/media\/releases\/2020\/p1218-overdose-deaths-covid-19.html","journal-title":"Overdose deaths accelerating during COVID-19: Expanded prevention efforts needed"},{"key":"e_1_3_1_10_1","unstructured":"Centers for Disease Control and Prevention. (2021.) About multiple cause of death 1999\u20132019 . http:\/\/wonder.cdc.gov\/mcd-icd10.html"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2017.1399403"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.6558"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3119"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.2143"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002922"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743720943820"},{"key":"e_1_3_1_17_1","author":"Kemp C","year":"2021","unstructured":"Kemp, C. (2021, January 19). New guidelines would make it easier for pediatricians to prescribe buprenorphine. https:\/\/www.aappublications.org\/news\/2021\/01\/19\/buprenorphine011921","journal-title":"New guidelines would make it easier for pediatricians to prescribe buprenorphine"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5523"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a4"},{"key":"e_1_3_1_21_1","volume-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019","unstructured":"National Academies of Sciences, Engineering, and Medicine. (2019). Medications for opioid use disorder save lives. The National Academies Press."},{"key":"e_1_3_1_22_1","author":"National Institute on Drug Abuse","year":"2017","unstructured":"National Institute on Drug Abuse. (2017). Impacts of drugs on neurotransmission. https:\/\/www.drugabuse.gov\/news-events\/nida-notes\/2017\/03\/impacts-drugs-neurotransmission","journal-title":"Impacts of drugs on neurotransmission"},{"key":"e_1_3_1_23_1","author":"National Institute on Drug Abuse","year":"2018","unstructured":"National Institute on Drug Abuse. (2018). Office-based buprenorphine treatment of OUD. https:\/\/www.drugabuse.gov\/videos\/facts-medication-treatment-opioid-use-disorder-oud","journal-title":"Office-based buprenorphine treatment of OUD"},{"key":"e_1_3_1_24_1","author":"National Institute on Drug Abuse","year":"2019","unstructured":"National Institute on Drug Abuse. (2019). The brain & the actions of cocaine, opioids, and marijuana. https:\/\/www.drugabuse.gov\/publications\/teaching-addiction-science\/brain-actions-cocaine-opioids-marijuana","journal-title":"The brain & the actions of cocaine, opioids, and marijuana"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare6020030"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-00921-9"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2016.03.002"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02829.x"},{"key":"e_1_3_1_31_1","author":"Substance Abuse and Mental Health Services Administration","year":"2019","unstructured":"Substance Abuse and Mental Health Services Administration. (2019). 2018 NSDUH annual national report.https:\/\/www.samhsa.gov\/data\/report\/2018-nsduh-annual-national-report","journal-title":"2018 NSDUH annual national report."},{"key":"e_1_3_1_32_1","author":"Substance Abuse and Mental Health Services Administration","year":"2020","unstructured":"Substance Abuse and Mental Health Services Administration. (2020). Naltrexone. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/naltrexone","journal-title":"Naltrexone"},{"key":"e_1_3_1_33_1","unstructured":"Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. Pub. L. No. 115-271. (2018). https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6"},{"key":"e_1_3_1_34_1","author":"U.S. Department of Health and Human Services","year":"2018","unstructured":"U.S. Department of Health and Human Services. (2018). Facing addiction in America. The Surgeon General's spotlight on opioids. https:\/\/addiction.surgeongeneral.gov","journal-title":"Facing addiction in America. The Surgeon General's spotlight on opioids"},{"key":"e_1_3_1_35_1","author":"U.S. Department of Health and Human Services","year":"2021","unstructured":"U.S. Department of Health and Human Services. (2021). HHS expands access to treatment for opioid use disorder: Eliminates certain X-waiver requirements for DEA-registered physicians. https:\/\/www.hhs.gov\/about\/news\/2021\/01\/14\/hhs-expands-access-to-treatment-for-opioiduse-disorder.html","journal-title":"HHS expands access to treatment for opioid use disorder: Eliminates certain X-waiver requirements for DEA-registered physicians"},{"key":"e_1_3_1_36_1","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. (2019). Information about medication-assisted treatment (MAT). https:\/\/www.fda.gov\/drugs\/information-drug-class\/information-about-medication-assisted-treatment-mat#:\u223c:text=There%20are%20three%20drugs%20approved,with%20counseling%20and%20psychosocial%20support","journal-title":"Information about medication-assisted treatment (MAT)"},{"key":"e_1_3_1_37_1","author":"U.S. Food and Drug Administration","year":"2021","unstructured":"U.S. Food and Drug Administration. (2021a). Probuphine: Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/204442s011lbl.pdf","journal-title":"Probuphine: Highlights of prescribing information"},{"key":"e_1_3_1_38_1","author":"U.S. Food and Drug Administration","year":"2021","unstructured":"U.S. Food and Drug Administration. (2021b). Vivitrol (naltrexone for extended-release injectable suspension): Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021897s052lbl.pdf","journal-title":"Vivitrol (naltrexone for extended-release injectable suspension): Highlights of prescribing information"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.08.007"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0898-0"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.24865"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40124-018-0161-z"}],"container-title":["Journal of Psychosocial Nursing and Mental Health Services"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T07:01:08Z","timestamp":1683097268000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/02793695-20210415-04"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.3928\/02793695-20210415-04"],"URL":"https:\/\/doi.org\/10.3928\/02793695-20210415-04","relation":{},"ISSN":["0279-3695","1938-2413"],"issn-type":[{"value":"0279-3695","type":"print"},{"value":"1938-2413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}